That is a big risk investors take when trying to find the winners and losers within the biotech sector. While we made the ...

Shares of Profusa (PFSA) hit a record low on Thursday, crashing 28% after the biotech company announced its second reverse ...

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

It might pull it off, provided several things fall right in place.

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

After years in the wilderness, this overlooked ASX biotech stock is winning back believers, with some analysts tipping gains ...